보고서 요약(국문)

시장 개요
전 세계 혈관육종 치료 시장은 2022년 2억 5,310만 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 6.4%의 성장률을 보이며 2030년에는 4억 1,230만 달러에 이를 것으로 예상됩니다.
혈관육종은 신체 어느 부위에서든 발생할 수 있지만, 피부, 유방, 간, 비장에서 가장 흔하게 발생합니다. 전 세계 혈관육종 치료 시장은 최근 표적 치료법의 도입으로 인해 상당한 성장을 보였습니다. 예를 들어, 혈관육종에서 조절되는 혈관 내피 성장 인자(VEGF)는 파조파닙(pazopanib) 및 레고라페닙(regorafenib)과 같은 티로신 키나제 억제제를 통해 표적 치료가 가능합니다.
또한, 임상 시험 증가, 협력 확대, 연구 개발 투자 증가와 같은 주요 성장 동력이 향후 시장 성장을 견인할 것으로 예상됩니다. 미국과 캐나다와 같은 국가에서 기술 발전이 크게 진전됨에 따라 북미 지역의 수요가 증가하고 있습니다. 암젠(Amgen Inc.), 일라이 릴리(Eli Lilly & Company), 제넨텍(Genentech Inc.) 등 주요 기업들이 활발하게 시장에서 활동하고 있습니다.
시장 동향
혈관육종 치료 연구 개발 증가
전 세계 혈관육종 치료 시장은 최근 다양한 연구 개발 덕분에 상당한 성장을 보였습니다. 혈관육종은 일반적으로 병력, 임상 및 영상 소견을 바탕으로 진단됩니다. 또한, 혈관육종 치료에 대한 첨단 연구 개발은 시장 성장을 가속화하는 데 기여하고 있습니다.
예를 들어, 2022년 11월에 발표된 "탁산 기반 화학방사선 요법으로 치료한 피부 혈관육종"이라는 제목의 논문에 따르면, 임상 연구에서 파클리탁셀과 도세탁셀과 같은 탁산 유도체 약물이 피부 혈관육종 치료의 1차 화학 요법으로 중요하다는 점이 시사되었습니다. 또한, 탁산을 이용한 화학방사선 요법은 수술이나 방사선 요법에 비해 높은 반응률과 전체 생존율의 상당한 향상을 보여주었습니다. 따라서 위의 요인들은 예측 기간 동안 시장 성장을 촉진하는 데 도움이 됩니다.
혈관육종 치료를 위한 기술 발전 증가
혈관육종은 혈관과 림프관의 내벽에서 발생하며, 주요 기업들의 주요 기술 발전은 시장 성장을 견인하는 데 도움이 됩니다. 피부는 가장 많이 영향을 받는 부위로, 전체 사례의 약 57.21%가 피부 혈관육종입니다. 이러한 효과적인 기술 발전은 연구 결과를 새로운 치료법으로 전환하고 수십억 명의 혈관육종 환자 치료를 개선하는 데 도움이 됩니다.
예를 들어, Springer Journal은 2023년 4월에 공간 전사체학(spatial transcriptomics)이 아시아인 두경부 혈관육종의 위상학적 면역 환경을 밝혀냈다는 논문을 발표했습니다. 이 연구는 10x Genomics Visium 플랫폼을 사용하여 UV 신호 및 HHV-7의 존재 여부로 특징지어지는 대표적인 사례에 대한 공간 전사체 프로파일링을 수행하여 혈관육종의 위상학적 종양 면역 환경을 밝혀냈습니다. 따라서 위의 요인들로 인해 시장은 예측 기간 동안 성장할 것으로 예상됩니다.

림프관육종 관련 합병증으로 인해 세계 시장 성장이 저해될 것으로 예상됩니다.
림프관육종의 합병증으로는 봉와직염, 근골격계 통증, 심리적 스트레스, 악성 종양 발생 위험 증가 등이 있습니다. 봉와직염은 경구 항생제 복용 시 흔히 발생하며, 피부 아래 진피 및 피하 조직의 세균 감염으로 림프관육종과 관련된 가장 흔한 합병증입니다. 따라서 이러한 요인들로 인해 향후 시장 성장이 저해될 것으로 예상됩니다.
세분화 분석
세계 혈관육종 치료 시장은 유형, 치료법, 최종 사용자 및 지역별로 세분화됩니다.
치료 부문 중 면역요법은 세계 혈관육종 치료 시장 점유율의 약 38.5%를 차지했습니다.
전 세계적으로 혈관육종 임상 시험이 증가함에 따라 혈관육종 치료에 대한 수요가 증가하고 있습니다. 면역요법은 면역 체계를 활성화하는 약물, 종양 세포를 표적으로 삼도록 면역 세포를 변형시키는 약물, 단클론 항체, 면역관문 억제제, 백신 등을 포함하며, 이러한 약물들이 일반적인 면역요법의 유형입니다.
예를 들어, clinicalTrials.gov에 따르면, 2023년 4월 5일 M.D. 앤더슨 암센터는 피부 혈관육종 치료를 위한 TH1 수지상 세포 면역요법 1상 임상시험을 진행했습니다. 이 임상시험의 주요 목적은 종양 용해물과 mRNA를 탑재한 자가 수지상 세포(DC)를 두경부 피부 혈관육종 환자에게 보조 요법으로 투여했을 때의 안전성, 독성 및 실현 가능성을 확인하는 것입니다. 이처럼 위의 요인들은 시장 성장을 가속화하는 데 도움이 됩니다.

지리적 시장 침투
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 최근 몇 년간 혈관육종 시장에서 상당한 비중을 유지해 왔으며, 의료비 지출 증가, 연구 개발 투자 확대, 혈관육종 치료 기술 발전 등의 요인으로 인해 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 미국 국민건강보험공단(NHEA)에 따르면 미국의 연간 총 의료비 지출은 2.7% 증가한 4조 3천억 달러에 달했습니다. 의사 진료비는 연평균 3.8% 증가했으며, 병원 서비스(4.5%)와 임상 서비스(6.6%)는 더 높은 성장률을 보였습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Novartis AG, Bayer AG, Sanofi, Amgen Inc., Eli Lilly and Company, Genentech Inc., Janssen Pharmaceuticals, AbbVie Inc., Bausch Health, GlaxoSmithKline Plc. 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 혈관육종 치료 시장에 상당한 영향을 미쳤습니다. 팬데믹이 한창일 때 많은 의료 시스템이 과부하 상태에 빠졌고, 긴급하지 않은 의료 시술 및 검진이 연기되거나 취소되었습니다. 이로 인해 혈관육종 치료 연구가 지연되었습니다. 임상 시험은 혈관육종 치료 시장에서 새로운 치료법을 개발하고 치료 결과를 개선하는 데 필수적입니다.
하지만 팬데믹으로 인해 많은 기관에서 환자 안전을 최우선으로 고려하여 등록을 일시적으로 중단하거나 프로토콜을 변경하면서 임상 시험 진행이 차질을 빚었습니다. 이로 인해 시험 완료 및 새로운 치료법의 출시가 지연되었습니다. 더욱이, 팬데믹 기간 동안 연구 개발 노력의 초점이 COVID-19 백신 및 치료제 개발에 크게 집중되면서 변화했습니다. 따라서 위와 같은 요인들로 인해 혈관육종 치료 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.
유형별
• 혈관육종
• 림프관육종
• 실질 혈관육종
치료법별
• 수술
• 방사선 치료
• 화학 요법
• 표적 치료
• 면역 요법
• 기타
최종 사용자별
• 병원
• 클리닉
• 외래 수술 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2020년 9월 ESMO 가상 학술대회에서 2상 바스켓 연구의 육종 코호트 데이터가 발표되었으며, 펨브롤리주맙 단독 요법이 무진행 생존 기간(PFS)을 연장하는 것으로 나타났습니다. • 상피육종, 혈관육종, 연골육종을 포함한 일부 희귀 육종 아형에서 발생합니다.

• 2020년 12월, 싱가포르 국립암센터(NCCS)의 임상 과학자들이 전 세계 연구 기관들과 협력하여 수행한 새로운 연구에서 혈관육종이 고유한 유전체 및 면역 프로필을 가지고 있어 세 가지 아형으로 분류될 수 있다는 사실이 밝혀졌습니다. 이러한 새로운 분류를 통해 환자에게 맞춤형 치료를 제공할 수 있습니다.

보고서 구매 이유:

• 유형, 치료법, 최종 사용자 및 지역별 글로벌 혈관육종 치료 시장 세분화를 시각화하고 주요 상업적 자산 및 업체를 파악하기 위함입니다.

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위함입니다.

• 모든 세그먼트를 포함한 글로벌 혈관육종 치료 시장의 다양한 데이터가 담긴 엑셀 시트가 제공됩니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서가 제공됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 혈관육종 치료 시장 보고서는 약 69개의 표, 70개의 그림, 그리고 195페이지 분량으로 구성됩니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
Global Angiosarcoma Treatment Market reached US$ 253.1 million in 2022 and is expected to reach US$ 412.3 million by 2030 growing with a CAGR of 6.4% during the forecast period 2023-2030.
Angiosarcoma can develop anywhere in the body but most often occur in the skin, breast, liver, and spleen. The global angiosarcoma treatment market has witnessed significant growth in recent years due to the adoption of targeted therapies. For instance, vascular endothelial growth factor which is regulated in angiosarcoma can be targeted by tyrosine kinase inhibitors such as pazopanib and regorafenib.
Furthermore, significant growth drivers such as increasing clinical trials, increasing collaborations, and research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Amgen Inc., Eli Lilly, and Company, Genentech Inc., and others are actively operating in the market.
Dynamics
Increasing Research and Developments for Angiosarcoma Treatment
The global angiosarcoma treatment market has witnessed significant growth due to various recent research and developments. Angiosarcoma is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating angiosarcoma help to accelerate market growth.
For instance, according an article entitled Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy published on November 2022 states that clinical studies have suggested the importance of taxane-derived agents such as paclitaxel and docetaxel as first-line chemotherapy for treatment of cutaneous angiosarcoma. In addition, chemoradiotherapy with taxanes achieved a high response rate with significant improvement in overall survival compared with surgery or radiotherapy. Thus, the above factors help to boost the market growth in the forecast period.
Rising Technological Advancements for Angiosarcoma Treatment
Angiosarcoma develops in the inner lining of blood vessels and lymph vessels and the major advancements from major companies help to drive market growth. Skin is the most affected area with approximately 57.21% of cases being cutaneous angiosarcoma. These effective advancements help to transform research discoveries into new treatments and improve care for billions of people with angiosarcoma.
For instance, Springer Journal published an article in April 2023, states that spatial transcriptomics reveals topological immune landscapes of Asian head and neck angiosarcoma. It involves spatial transcriptomic profiling using the 10x Genomics Visium platform that is performed on representative cases characterized by the presence or absence of UV signatures and HHV-7 by revealing the topological tumor immune landscape of angiosarcoma. Thus, owing to the above factors the market is expected to boost over the forecast period.
Complications Associated with Lymphangiosarcoma is Expected to Hamper Global Market Growth
Complications of lymphangiosarcoma include cellulitis, musculoskeletal pain, psychological stress, and an increased risk of malignancy. Cellulitis usually occurs with oral antibiotics and cellulitis is a bacterial infection of the dermis and subcutaneous tissues underneath the skin and is the most common complication associated with lymphangiosarcoma. Thus, owing to the above factors the market is expected to hamper over the forecast period.
Segment Analysis
The global angiosarcoma treatment market is segmented based on type, treatment, end users, and region.
Immunotherapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Angiosarcoma Treatment Market Share
The rising clinical trials of angiosarcoma globally have contributed to the growing demand for angiosarcoma treatment. Immunotherapy includes drugs that activate the immune system that modify the immune system cells to target tumor cells and monoclonal antibodies, checkpoint inhibitors, and vaccines are the common types of immunotherapies.
For instance, according to clinicalTrials.gov, on April 5, 2023, M.D. Anderson Cancer Center conducted a clinical trial on Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma. The main aim is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head & neck angiosarcoma as adjuvant therapy. Thus, the above factors help to acceleratethe market growth.
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share in 2022
North America has maintained a significant proportion of the angiosarcoma market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as an increase in healthcare expenditures, increasing research and developments, and technological advancements in angiosarcoma treatment.
For instance, according to the National Health Expenditure Account (NHEA), the total annual healthcare expenditure in the United States is increased by 2.7% to $4.3 trillion. Physician spending grew by an average of 3.8% per year while hospital services (4.5%) and clinical services (6.6%) had higher growth rates.
Competitive Landscape
The major global players in the market include Novartis AG,Bayer AG,Sanofi,Amgen Inc.,Eli Lilly and Company,Genentech Inc.,Janssen Pharmaceuticals, AbbVie Inc, Bausch Health, GlaxoSmithKline Plc.among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the angiosarcoma treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in angiosarcoma treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the angiosarcoma treatment market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the angiosarcoma treatment market is expected to be moderately affected over the forecast period.
By Type
• Hemangiosarcoma
• Lymphangiosarcoma
• Parenchymal Angiosarcoma
By Treatment
• Surgery
• Radiotherapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others
By End Users
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In September 2020, during the ESMO Virtual Congress, data from the sarcoma cohort of the phase 2 basket study is presented and showed that pembrolizumab monotherapy prolonged progression-free survival (PFS) in selected rare sarcoma subtypes including epithelioid sarcoma, angiosarcoma, and chondrosarcoma.
• In December 2020, a new study led by clinician-scientists from the National Cancer Centre Singapore (NCCS) with collaborators from research institutions worldwide found that angiosarcomas have unique genomic and immune profiles which allow them to be classified into three different subtypes. With this new classification, patients can be treated using a personalized-medicine approach.
Why Purchase the Report?
• To visualize the global angiosarcoma treatment market segmentation based on the type, treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of globalangiosarcoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global angiosarcoma treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End Users
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing research and developments for angiosarcoma treatment
4.1.1.2. Rising technological advancements for angiosarcoma treatment
4.1.2. Restraints
4.1.2.1. Complications associated with lymphangiosarcoma
4.1.3. Opportunity
4.1.3.1. Emerging markets of angiosarcoma treatments
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Hemangiosarcoma*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Lymphangiosarcoma
7.4. Parenchymal Angiosarcoma
8. By Treatment
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Surgery
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Radiotherapy
8.4. Chemotherapy
8.5. Targeted Therapy
8.6. Immunotherapy
8.7. Others
9. By End Users
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.1.2. Market Attractiveness Index, By End Users
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Ambulatory Surgical Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7. Brazil
10.4.7.1. Argentina
10.4.7.2. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),ByTreatment
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.7. China
10.5.7.1. India
10.5.7.2. Japan
10.5.7.3. Australia
10.5.7.4. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Product Benchmarking
11.3. Company Share Analysis
11.4. Key Developments and Strategies
12. Company Profiles
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Bayer AG
12.3. Sanofi
12.4. Amgen Inc.
12.5. Eli Lilly and Company
12.6. Genentech Inc.
12.7. Janssen Pharmaceuticals
12.8. AbbVie Inc.
12.9. Bausch Health
12.10. GlaxoSmithKline Plc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Novartis AG, 4.	Key Developments, Bayer AG, Sanofi, Amgen Inc., Eli Lilly and Company, Genentech Inc., Janssen Pharmaceuticals, AbbVie Inc., Bausch Health, GlaxoSmithKline Plc.

표 목록 (Tables)

List of Tables Table 1 Global Angiosarcoma Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Angiosarcoma Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Angiosarcoma Treatment Market Value, By End Users, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Angiosarcoma Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Angiosarcoma Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Angiosarcoma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 7 Global Angiosarcoma Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Angiosarcoma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 9 Global Angiosarcoma Treatment Market Value, By End Users, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Angiosarcoma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 11 Global Angiosarcoma Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Angiosarcoma Treatment Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Angiosarcoma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 14 North America Angiosarcoma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 15 North America Angiosarcoma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 16 North America Angiosarcoma Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Angiosarcoma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 18 South America Angiosarcoma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 19 South America Angiosarcoma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 20 South America Angiosarcoma Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Angiosarcoma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 Europe Angiosarcoma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 23 Europe Angiosarcoma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 24 Europe Angiosarcoma Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Angiosarcoma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Angiosarcoma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Angiosarcoma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Angiosarcoma Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Angiosarcoma Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Angiosarcoma Treatment Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Angiosarcoma Treatment Market Value, By End Users, 2021-2030 (US$ Billion)

Table 32 Novartis AG: Overview

Table 33 Novartis AG: Product Portfolio

Table 34 Novartis AG: Key Developments

Table 35 Bayer AG: Overview

Table 36 Bayer AG: Product Portfolio

Table 37 Bayer AG: Key Developments

Table 38 Sanofi: Overview

Table 39 Sanofi: Product Portfolio

Table 40 Sanofi: Key Developments

Table 41 Amgen Inc.: Overview

Table 42 Amgen Inc.: Product Portfolio

Table 43 Amgen Inc.: Key Developments

Table 44 Eli Lilly and Company: Overview

Table 45 Eli Lilly and Company: Product Portfolio

Table 46 Eli Lilly and Company: Key Developments

Table 47 Genentech Inc.: Overview

Table 48 Genentech Inc.: Product Portfolio

Table 49 Genentech Inc.: Key Developments

Table 50 Janssen Pharmaceuticals: Overview

Table 51 Janssen Pharmaceuticals: Product Portfolio

Table 52 Janssen Pharmaceuticals: Key Developments

Table 53 AbbVie Inc: Overview

Table 54 AbbVie Inc: Product Portfolio

Table 55 AbbVie Inc: Key Developments

Table 56 Bausch Health: Overview

Table 57 Bausch Health: Product Portfolio

Table 58 Bausch Health: Key Developments

Table 59 GlaxoSmithKline Plc.: Overview

Table 60 GlaxoSmithKline Plc.: Product Portfolio

Table 61 GlaxoSmithKline Plc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Angiosarcoma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Angiosarcoma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 4 Global Angiosarcoma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 5 Global Angiosarcoma Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Angiosarcoma Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 7 Hemangiosarcoma Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 8 Lymphangiosarcoma Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 9 Parenchymal Angiosarcoma Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 10 Global Angiosarcoma Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 11 Surgery Treatment in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 12 Radiotherapy Treatment in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 13 Chemotherapy Treatment in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 14 Targeted Therapy Treatment in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 15 Immunotherapy Treatment in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 16 Others Treatment in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 17 Global Angiosarcoma Treatment Market Y-o-Y Growth, By End Users, 2022-2030 (%)

Figure 18 Hospitals End Users in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 19 Clinics End Users in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 20 Ambulatory Surgical Center End Users in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 21 End Users in Global Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 22 Global Angiosarcoma Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 24 Asia-Pacific Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 25 Europe Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 26 South America Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 27 Middle East and Africa Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 28 North America Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 29 North America Angiosarcoma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 30 North America Angiosarcoma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 31 North America Angiosarcoma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 32 North America Angiosarcoma Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 33 South America Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 34 South America Angiosarcoma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 35 South America Angiosarcoma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 36 South America Angiosarcoma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 37 South America Angiosarcoma Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 39 Europe Angiosarcoma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 40 Europe Angiosarcoma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 41 Europe Angiosarcoma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 42 Europe Angiosarcoma Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 43 Asia-Pacific Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 44 Asia-Pacific Angiosarcoma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 45 Asia-Pacific Angiosarcoma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 46 Asia-Pacific Angiosarcoma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 47 Asia-Pacific Angiosarcoma Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 48 Middle East & Africa Angiosarcoma Treatment Market Value, 2021-2030 (US$ Billion)

Figure 49 Middle East & Africa Angiosarcoma Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 50 Middle East & Africa Angiosarcoma Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 51 Middle East & Africa Angiosarcoma Treatment Market Share, By End Users, 2022 & 2030 (%)

Figure 52 Novartis AG: Financials

Figure 53 Bayer AG: Financials

Figure 54 Sanofi: Financials

Figure 55 Amgen Inc.: Financials

Figure 56 Eli Lilly and Company: Financials

Figure 57 Genentech Inc.: Financials

Figure 58 Janssen Pharmaceuticals: Financials

Figure 59 AbbVie Inc: Financials

Figure 60 Bausch Health: Financials

Figure 61 GlaxoSmithKline Plc.: Financials

글로벌 혈관육종 치료 시장 – 2023-2030

Global Angiosarcoma Treatment Market - 2023-2030